Top

BY Jill Russell, Ph.D.

Researchers at The University of Texas MD Anderson Cancer Center have discovered important mechanisms of drug resistance and metastasis in triple-negative breast cancer. Gloria Echeverria, Ph.D., instructor in Experimental Radiation Oncology, presents these findings today at the 2019 San Antonio Breast Cancer Symposium, which provide possible leads for improving breast cancer treatment.

Triple-negative breast cancer is extremely...

A triple-negative breast cancer cell in the process of dying under attack from a combination of drugs in a laboratory experiment. Image: National Cancer Institute

BY Clayton Boldt, Ph. D.

MD Anderson’s adoptive cell therapy (ACT) platform is advancing the next generation of cell-based immune therapies to bring innovative approaches...

BY Clayton Boldt, Ph. D.

Each year in the U.S., more than 50,000 people will be diagnosed with pancreatic cancer, which ranks around the 10th most common cancer type...

BY Clayton Boldt, Ph.D.

Cancer’s ability to evolve in response to treatment and develop resistance to available therapies is one of the most significant challenges for clinicians to successfully treat the disease. Combination treatments may be helpful, but it’s also critical for researchers to study how a tumor responds to cancer treatment over time in order to best overcome those resistance mechanisms.

The Adaptive Patient-Oriented Longitudinal Learning...

“The longitudinal component of collection is the key,” says APOLLO co-leader Ignacio Wistuba, M.D., for tumor and blood samples to reveal how cancer changes over time to resist treatment.

BY Clayton Boldt, Ph.D.

Glioblastoma (GBM) is not among the most commonly diagnosed cancers in the U.S., but it can certainly be among the most devastating. Of the...

BY Clayton Boldt, Ph. D.

Building upon the foundational discovery that the targeted therapy poziotinib is a potent and selective inhibitor of specific EGFR and HER2...

BY Clayton Boldt

Multiple myeloma is the second most common hematological malignancy in the United States, and it’s increasing in incidence. An estimated 32,110...

BY Scott Merville

Small precancerous growths in the lungs are capable of progressing to invasive lung cancer, but so little has been known about them that understanding...

BY Clayton R. Boldt, Ph.D.

An international consortium, led in part by clinicians and researchers from The University of Texas MD Anderson Cancer Center, has published...

BY Clayton Boldt, Ph.D.

Leukemia researchers at The University of Texas MD Anderson Cancer Center, working collaboratively with the Therapeutics Discovery division...